Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | May 28, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date May 28, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Cambridge Innovation Capital (Jersey) Limited | 1,751,437 |
Last balance in matching sequence
After 2019-05-28 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-05-28 · Conversion · Acquired 1,081,823 · Balance 1,081,823 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Row 2 · 2019-05-28 · Other · Acquired 125,587 · Balance 1,207,410 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Row 3 · 2019-05-28 · Conversion · Acquired 229,741 · Balance 1,437,151 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Row 4 · 2019-05-28 · Purchase · Acquired 314,286 · Balance 1,751,437 F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. |
| Series B1 Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Cambridge Innovation Capital (Jersey) Limited | 0 |
Reported balance
After 2019-05-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-05-28 · Conversion · Acquired 1,081,823 · Balance 0 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. |
| Series B1 Preferred Shares WarrantsSEC Table II · derivative / convertible security | IndirectBy Cambridge Innovation Capital (Jersey) Limited | 0 |
Reported balance
After 2019-05-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-05-28 · Other · Acquired 125,587 · Balance 0 F3: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. |
| Series B2 Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Cambridge Innovation Capital (Jersey) Limited | 0 |
Reported balance
After 2019-05-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-05-28 · Conversion · Acquired 229,741 · Balance 0 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
F2: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc.
F3: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B2 Preferred Shares · Derivative | 229,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · derivative · entry 7 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 0 Underlying: Ordinary Shares · 229,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherSeries B1 Preferred Shares Warrants · Derivative | 125,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · derivative · entry 6 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 0 Underlying: Ordinary Shares · 125,587 shares Expires not disclosed F3 · security: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.underlying: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B1 Preferred Shares · Derivative | 1,081,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · derivative · entry 5 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 0 Underlying: Ordinary Shares · 1,081,823 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | PurchaseOrdinary Shares | 314,286 | $14.00 | $4,400,004.00 |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · nonDerivative · entry 4 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 1,751,437 F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 229,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · nonDerivative · entry 3 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 1,437,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherOrdinary Shares | 125,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · nonDerivative · entry 2 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 1,207,410 F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 1,081,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032916 · a4.xml · nonDerivative · entry 1 Anstey Michael · CIK 0001776856 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cambridge Innovation Capital (Jersey) Limited Disclosed balance after: 1,081,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.